gossypol has been researched along with Bone Cancer in 5 studies
Gossypol: A dimeric sesquiterpene found in cottonseed (GOSSYPIUM). The (-) isomer is active as a male contraceptive (CONTRACEPTIVE AGENTS, MALE) whereas toxic symptoms are associated with the (+) isomer.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with metastatic prostate cancer scheduled to start, or who had recently (within 6 weeks) initiated, ADT were enrolled." | 2.82 | A Phase II Study of AT-101 to Overcome Bcl-2--Mediated Resistance to Androgen Deprivation Therapy in Patients With Newly Diagnosed Castration-Sensitive Metastatic Prostate Cancer. ( DiPaola, RS; Goodin, S; Hussain, M; Jeyamohan, C; Kaufman, HL; Liu, G; Mehnert, J; Stadler, WM; Stein, MN; Tereshchenko, IV, 2016) |
| "AT-101 (A), a small molecule oral inhibitor of the Bcl-2 family, has activity alone and in combination with docetaxel (Taxotere) and prednisone (DP) in metastatic castration-resistant prostate cancer (mCRPC)." | 2.77 | Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer. ( Berry, WR; Brookes, M; Burke, JM; Caton, JR; Fleming, MT; Galsky, MD; Holmlund, JT; Hutson, TE; Karlov, P; Leopold, L; Matveev, V; Sonpavde, G; Wood, BA, 2012) |
| "Gossypol, which is a natural polyphenolic aldehyde isolated from the seeds of the cotton plant, has been shown to exert antitumoral activity in leukemia and lymphoma and in breast, head and neck, colon and prostate cancers." | 1.56 | In vivo and in vitro inhibition of osteosarcoma growth by the pan Bcl-2 inhibitor AT-101. ( Bei, R; Benvenuto, M; Cerbelli, B; Ciuffa, S; Fazi, S; Izzi, V; Lucarelli, E; Masuelli, L; Mattera, R; Modesti, A; Potenza, V; Tresoldi, I; Zago, E, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Masuelli, L | 1 |
| Benvenuto, M | 1 |
| Izzi, V | 1 |
| Zago, E | 1 |
| Mattera, R | 1 |
| Cerbelli, B | 1 |
| Potenza, V | 1 |
| Fazi, S | 1 |
| Ciuffa, S | 1 |
| Tresoldi, I | 1 |
| Lucarelli, E | 1 |
| Modesti, A | 1 |
| Bei, R | 1 |
| Stein, MN | 1 |
| Hussain, M | 1 |
| Stadler, WM | 1 |
| Liu, G | 1 |
| Tereshchenko, IV | 1 |
| Goodin, S | 1 |
| Jeyamohan, C | 1 |
| Kaufman, HL | 1 |
| Mehnert, J | 1 |
| DiPaola, RS | 1 |
| Pond, GR | 1 |
| Armstrong, AJ | 1 |
| Wood, BA | 2 |
| Brookes, M | 2 |
| Leopold, L | 2 |
| Berry, WR | 2 |
| de Wit, R | 1 |
| Eisenberger, MA | 1 |
| Tannock, IF | 1 |
| Sonpavde, G | 2 |
| Matveev, V | 1 |
| Burke, JM | 1 |
| Caton, JR | 1 |
| Fleming, MT | 1 |
| Hutson, TE | 1 |
| Galsky, MD | 1 |
| Karlov, P | 1 |
| Holmlund, JT | 1 |
| Jackson, RS | 1 |
| Placzek, W | 1 |
| Fernandez, A | 1 |
| Ziaee, S | 1 |
| Chu, CY | 1 |
| Wei, J | 1 |
| Stebbins, J | 1 |
| Kitada, S | 1 |
| Fritz, G | 1 |
| Reed, JC | 1 |
| Chung, LW | 1 |
| Pellecchia, M | 1 |
| Bhowmick, NA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double Blind, Placebo-controlled Multiple-center Phase III Trial of Gossypol Combined With Docetaxel and Cisplatin Scheme in Advanced Non Small-cell Lung Cancers With APE1 High Expression[NCT01977209] | Phase 3 | 204 participants (Anticipated) | Interventional | 2013-09-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for gossypol and Bone Cancer
| Article | Year |
|---|---|
A Phase II Study of AT-101 to Overcome Bcl-2--Mediated Resistance to Androgen Deprivation Therapy in Patients With Newly Diagnosed Castration-Sensitive Metastatic Prostate Cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy | 2016 |
Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neopla | 2012 |
3 other studies available for gossypol and Bone Cancer
| Article | Year |
|---|---|
In vivo and in vitro inhibition of osteosarcoma growth by the pan Bcl-2 inhibitor AT-101.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Bone Neoplasms; Cell Line, Tumor; Cell Prolife | 2020 |
Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Clinical Trials as Topic; Dise | 2012 |
Sabutoclax, a Mcl-1 antagonist, inhibits tumorigenesis in transgenic mouse and human xenograft models of prostate cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Cell Transformation, Neoplastic; Disease | 2012 |